文献速递其他结缔组织病

循环CCL2预测早期系统性硬化症相关间质性肺病的长期进展:两项独立队列数据

CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.
PubMed 文献 · Arthritis Rheumatol · 2017-08-08

在266例早期系统性硬化症(SSc)患者中发现队列中,校正年龄、性别和种族后,循环CCL2和IL-10是间质性肺病(ILD)进展的显著预测因子;CCL2较高预测用力肺活量占预计值百分比(FVC%)下降更快且生存更差。在171例早期SSc复制队列中,CCL2较高同样预测FVC%下降更快和生存更差,而IL-10和IL-6无预测意义。

要点

  • 循环CCL2较高预测早期SSc患者FVC%下降更快,两项独立队列结果一致。
  • 循环CCL2较高预测早期SSc患者生存更差,两项队列均显示显著关联。
  • IL-10较高在发现队列预测FVC%下降更慢,但复制队列无预测意义。

核心结论

  • 循环CCL2水平较高可预测早期SSc患者ILD进展和生存更差,支持CCL2作为生物标志物和潜在治疗靶点。

研究设计与样本

  • 发现队列为GENISOS中266例早期SSc患者,检测11种Th1/Th2细胞因子血浆水平。
  • 复制队列为CSRG中171例早期SSc患者,检测CCL2、IL-10和IL-6水平。
  • 主要结局为FVC%随时间的下降,并对纵向FVC%值与生存进行联合分析。

主要发现

  • 发现队列中,校正年龄、性别和种族后,CCL2和IL-10是ILD进展的显著预测因子。
  • 发现队列中,CCL2较高预测FVC%下降更快(b = -0.57,P = 0.032),IL-10较高预测FVC%下降更慢(b = 0.26,P = 0.01)。
  • 发现队列中,CCL2较高预测生存更差(风险比1.76,P = 0.030)。
  • 复制队列中,CCL2较高预测FVC%下降更快(b = -0.58,P = 0.038),但IL-10和IL-6无预测意义。
  • 复制队列中,CCL2较高预测生存更差(风险比3.89,P = 0.037)。

关键数值与推荐

  • 发现队列中CCL2预测FVC%下降的回归系数b = -0.57(P = 0.032),IL-10的b = 0.26(P = 0.01)。
  • 发现队列中CCL2预测生存的风险比为1.76(P = 0.030)。
  • 复制队列中CCL2预测FVC%下降的b = -0.58(P = 0.038)。
  • 复制队列中CCL2预测生存的风险比为3.89(P = 0.037)。

临床怎么用

  • 在早期SSc患者中,可考虑检测循环CCL2水平以辅助识别ILD进展和生存预后较差的高风险患者。
  • CCL2作为潜在治疗靶点的价值尚需进一步研究验证。

局限性

  • 发现队列检测11种细胞因子,复制队列仅检测CCL2、IL-10和IL-6,两队列检测指标不完全一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There are few clinical predictors of the progression of systemic sclerosis (SSc)-related interstitial lung disease (ILD). The purpose of this study was to examine the predictive significance of key cytokines for long-term progression of ILD and survival in 2 independent cohorts of patients with early SSc. METHODS: Plasma levels of 11 Th1/Th2 cytokines (interleukin-1β [IL-1β], IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, tumor necrosis factor, CCL2, interferon-inducible T cell α chemoattractant, and interferon-γ-inducible 10-kd protein) were measured in 266 patients with early SSc in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) discovery cohort. Levels of CCL2, IL-10, and IL-6 were measured in 171 patients with early SSc in the Canadian Scleroderma Research Group (CSRG) replication cohort. The primary outcome measure was a decline in the forced vital capacity percent predicted (FVC%) value over time. A joint analysis of longitudinal FVC% values and survival was performed. RESULTS: After adjustment for age, sex, and ethnicity, CCL2 and IL-10 were found to be significant predictors of ILD progression in the discovery cohort. Higher CCL2 levels predicted a faster decline in FVC% values (b = -0.57, P = 0.032), while higher IL-10 levels predicted a slower decline (b = 0.26, P = 0.01). A higher CCL2 value was also predictive of poorer survival (hazard ratio 1.76, P = 0.030). In the CSRG replication cohort, higher CCL2 levels predicted a faster decline in FVC% values (b = -0.58, P = 0.038), but neither IL-10 nor IL-6 had predictive significance. A higher CCL2 level also predicted poorer survival (hazard ratio 3.89, P = 0.037). CONCLUSION: Higher CCL2 levels in the circulation were predictive of ILD progression and poorer survival in patients with early SSc, findings that support the notion that CCL2 has a role as a biomarker and potential therapeutic target.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wu M, Baron M, Pedroza C, et al. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. Arthritis Rheumatol. 2017. PMID: 28575534. doi:10.1002/art.40171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。